Back to Search Start Over

Hepatitis C Virus NAT-Positive Solid Organ Allografts Transplanted Into Hepatitis C Virus-Negative Recipients: A Real-World Experience

Authors :
Joshua J. Shaw
Xaralambos Zervos
Salwa Rhazouani
Cristiano Quintini
Nikhil Kapila
Kawtar Al-Khalloufi
Neerja Agrawal
Viviana Navas
Carla Murgas
Diego Reino
K. V. Narayanan Menon
Christina C. Lindenmeyer
Michael Castillo
Asad Ur Rahman
Jason M. Vanatta
Samer Ebaid
Cedric Sheffield
Charles Miller
Source :
Hepatology (Baltimore, Md.)References. 72(1)
Publication Year :
2019

Abstract

Background and aims Hepatitis C virus (HCV)-viremic organs are underutilized, and there is limited real-world experience on the transplantation of HCV-viremic solid organs into recipients who are HCV negative. Approach and results Patients listed or being evaluated for solid organ transplant after January 26, 2018, were educated and consented by protocol on the transplantation of HCV-viremic organs. All recipients were HCV nucleic acid test and anti-HCV antibody negative at the time of transplant and received an HCV-viremic organ. The primary outcome was sustained virological response (SVR) at 12 weeks after completion of direct-acting antiviral (DAA) therapy (SVR12 ). Seventy-seven patients who were HCV negative underwent solid organ transplantation from a donor who was HCV viremic. No patients had evidence of advanced hepatic fibrosis. Treatment regimen and duration were at the discretion of the hepatologist. Sixty-four patients underwent kidney transplant (KT), and 58 KT recipients had either started or completed DAA therapy. Forty-one achieved SVR12 , 10 had undetectable viral loads but are not eligible for SVR12 , and 7 remain on treatment. One KT recipient was a nonresponder because of nonstructural protein 5A resistance. Four patients underwent liver transplant and 2 underwent liver-kidney transplant. Three patients achieved SVR12 , 1 has completed DAA therapy, and 2 remain on treatment. Six patients underwent heart transplant and 1 underwent heart-kidney transplant. Six patients achieved SVR12 and 1 patient remains on treatment. Conclusions Limited data exist on the transplantation of HCV-viremic organs into recipients who are HCV negative. Our study is the largest to describe a real-world experience of the transplantation of HCV-viremic organs into recipients who are aviremic. In carefully selected patients, the use of HCV-viremic grafts in the DAA era appears to be efficacious and well tolerated.

Details

ISSN :
15273350
Volume :
72
Issue :
1
Database :
OpenAIRE
Journal :
Hepatology (Baltimore, Md.)References
Accession number :
edsair.doi.dedup.....9cfb790e3848f82962a5780c6223abb3